



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	89.61
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	-0.30 (0.334%)
Day Range	89.28 - 91.00
52-Week Range	86.55 - 147.17
Volume	15,039,324

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Mar 6, 2018*  
[Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy](#)
- Mar 5, 2018*  
[Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.](#)
- Feb 27, 2018*  
[Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis](#)
- Feb 27, 2018*  
[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)
- Feb 21, 2018*  
[Celgene Receives Antitrust Clearance for Juno Acquisition](#)

## Financials [\[ View all \]](#)

- Feb 7, 2018*  
[Annual Report \(10-K\)](#)
- Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)